TuHURA Biosciences (HURA) Competitors $3.00 -0.09 (-2.91%) Closing price 04:00 PM EasternExtended Trading$3.02 +0.02 (+0.50%) As of 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock HURA vs. GOSS, ERAS, RGNX, AQST, YMAB, HUMA, VIGL, EOLS, CYRX, and MBXShould you be buying TuHURA Biosciences stock or one of its competitors? The main competitors of TuHURA Biosciences include Gossamer Bio (GOSS), Erasca (ERAS), REGENXBIO (RGNX), Aquestive Therapeutics (AQST), Y-mAbs Therapeutics (YMAB), Humacyte (HUMA), Vigil Neuroscience (VIGL), Evolus (EOLS), CryoPort (CYRX), and MBX Biosciences (MBX). These companies are all part of the "pharmaceutical products" industry. TuHURA Biosciences vs. Its Competitors Gossamer Bio Erasca REGENXBIO Aquestive Therapeutics Y-mAbs Therapeutics Humacyte Vigil Neuroscience Evolus CryoPort MBX Biosciences Gossamer Bio (NASDAQ:GOSS) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings. Is GOSS or HURA more profitable? TuHURA Biosciences has a net margin of 0.00% compared to Gossamer Bio's net margin of -344.81%. TuHURA Biosciences' return on equity of -390.35% beat Gossamer Bio's return on equity.Company Net Margins Return on Equity Return on Assets Gossamer Bio-344.81% -1,774.72% -46.73% TuHURA Biosciences N/A -390.35%-254.97% Which has preferable earnings and valuation, GOSS or HURA? TuHURA Biosciences has lower revenue, but higher earnings than Gossamer Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGossamer Bio$114.70M3.81-$56.53M-$0.62-3.10TuHURA BiosciencesN/AN/A-$21.68MN/AN/A Do institutionals and insiders believe in GOSS or HURA? 81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 6.7% of Gossamer Bio shares are held by company insiders. Comparatively, 0.2% of TuHURA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts recommend GOSS or HURA? Gossamer Bio presently has a consensus price target of $8.50, indicating a potential upside of 342.71%. TuHURA Biosciences has a consensus price target of $12.67, indicating a potential upside of 322.22%. Given Gossamer Bio's higher possible upside, research analysts plainly believe Gossamer Bio is more favorable than TuHURA Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00TuHURA Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40 Which has more risk & volatility, GOSS or HURA? Gossamer Bio has a beta of 1.96, indicating that its stock price is 96% more volatile than the S&P 500. Comparatively, TuHURA Biosciences has a beta of 0.04, indicating that its stock price is 96% less volatile than the S&P 500. Does the media refer more to GOSS or HURA? In the previous week, TuHURA Biosciences had 2 more articles in the media than Gossamer Bio. MarketBeat recorded 6 mentions for TuHURA Biosciences and 4 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 0.45 beat TuHURA Biosciences' score of -0.03 indicating that Gossamer Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TuHURA Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryGossamer Bio beats TuHURA Biosciences on 8 of the 14 factors compared between the two stocks. Get TuHURA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for HURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HURA vs. The Competition Export to ExcelMetricTuHURA BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$131.04M$3.07B$5.76B$9.65BDividend YieldN/A2.22%3.91%4.09%P/E RatioN/A20.4830.7825.12Price / SalesN/A355.18456.64116.46Price / CashN/A41.5625.2228.45Price / Book8.829.549.375.95Net Income-$21.68M-$54.74M$3.26B$265.46M7 Day Performance-7.69%2.39%1.88%0.96%1 Month Performance14.50%4.60%3.73%2.47%1 Year PerformanceN/A9.17%28.93%20.24% TuHURA Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HURATuHURA Biosciences1.793 of 5 stars$3.00-2.9%$12.67+322.2%N/A$131.04MN/A0.00N/ANews CoverageEarnings ReportGOSSGossamer Bio3.9189 of 5 stars$1.73-1.5%$8.50+390.5%+134.2%$400.19M$114.70M-2.80180ERASErasca2.3431 of 5 stars$1.48+5.7%$4.57+208.9%-45.4%$396.60MN/A-2.39120News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionRGNXREGENXBIO4.2798 of 5 stars$7.46-5.0%$28.38+280.4%-28.9%$396.54M$83.33M-2.17370News CoverageAnalyst ForecastGap DownAQSTAquestive Therapeutics2.0519 of 5 stars$3.86-1.0%$10.14+162.8%-1.4%$387.38M$57.56M-6.54160YMABY-mAbs Therapeutics2.6802 of 5 stars$8.52+0.1%$11.16+31.0%-30.4%$385.36M$87.68M-17.04150HUMAHumacyte1.9722 of 5 stars$1.75-29.4%$11.71+569.4%-72.2%$384.70M$1.57M-2.54150Analyst DowngradeGap DownHigh Trading VolumeVIGLVigil Neuroscience2.7038 of 5 stars$8.05flat$10.80+34.2%N/A$383.91MN/A-3.9340EOLSEvolus4.0291 of 5 stars$5.77-2.2%$21.25+268.3%-53.4%$381.64M$266.27M-5.89170Insider TradeGap UpCYRXCryoPort3.6153 of 5 stars$8.09+7.0%$12.00+48.3%-2.4%$379.04M$228.38M6.081,186MBXMBX Biosciences2.5529 of 5 stars$11.26-7.4%$37.63+234.1%N/A$376.35MN/A-2.4836 Related Companies and Tools Related Companies GOSS Competitors ERAS Competitors RGNX Competitors AQST Competitors YMAB Competitors HUMA Competitors VIGL Competitors EOLS Competitors CYRX Competitors MBX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HURA) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TuHURA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TuHURA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access